ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1108

The Serum CTRP9 Concentration Correlates with Cardiovascular Risk in Renal Allograft Recipients

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Miyatake, Nobuhiko, Kanazawa Medical University, Uchinada, Japan
  • Adachi, Hiroki, Kanazawa Medical University, Uchinada, Japan
  • Okada, Keiichiro, Kanazawa Medical University, Uchinada, Japan
  • Okino, Kazuaki, Kanazawa Medical University, Uchinada, Japan
  • Fujimoto, Keiji, Kanazawa Medical University, Uchinada, Japan
  • Furuichi, Kengo, Kanazawa Medical University, Uchinada, Japan
  • Yokoyama, Hitoshi, Kanazawa Medical University, Uchinada, Japan
Background

Cardiovascular disease (CVD) due to atherosclerosis is a major cause of death in renal allograft recipients. Recently, C1q/TNF-α related protein-9 (CTRP9), which is a paralog of adiponectin (ADPN), has been suggested to be related to the suppression of atherosclerosis and the occurrence of CVD, but this relationship has not been confirmed in renal allograft recipients. We evaluated the relationships among the serum CTRP9 concentration, serum ADPN concentration, and vascular calcification were investigated in 50 Japanese kidney allograft recipients.

Methods

Calcification of the abdominal aorta was evaluated according to the aortic calcification area index (ACAI) calculated from CT images. Changes in the serum CTRP9 and ADPN fractions and ACAI were examined for 8 years. In addition, the expression of CTRP9 and ADPN and their respective receptors AdipoR1 and R2 in small arteries of the transplanted kidney was examined by immunofluorescence.

Results

In renal allograft recipients, the serum CTRP9 concentration at the start of the observation was not significant correlated with eGFR or serum high-molecular-weight (HMW)-ADPN concentration (rS=-0.009, p=0.950; rS=-0.226, p=0.114, respectively). However, the change in the serum CTRP9 concentration was positively correlated with the change in the serum HMW-ADPN concentration (rS=0.315, p=0.026) and negatively correlated with the change in ACAI (rS=-0.367, p=0.009). Multiple regression analysis revealed that the serum HMW-ADPN concentration was a significant positive factor for the change in the serum CTRP9 concentration. Moreover, for ACAI, an increase in the serum CTRP9 concentration was an improving factor, but aging was an exacerbating factor. Furthermore, colocalization of CTRP9 and AdipoR1 was noted in intrarenal arterial endothelial cells.

Conclusion

In renal allograft recipients, CTRP9 and HMW-ADPN were suggested to produce vascular protective effects mediated by AdipoR1 to suppress the progression of aortic calcification.

Funding

  • Government Support - Non-U.S.